

# Global Pediatric Ophthalmology Congress

June 06-07, 2016 London, UK

## Intravitreal bevacizumab (Avastin) with peripheral retinal cryotherapy for patients with posterior retinopathy of prematurity and vitreous hemorrhage

**Mohamed Mostafa Kamel Diab**  
Ain Shams University, Egypt

**Purpose:** To report the short-term anatomic response of intravitreal bevacizumab (Avastin) and peripheral cryotherapy for the treatment of posterior retinopathy of prematurity (ROP) with vitreous hemorrhage in a small series of patients.

**Patients & Methods:** This was a retrospective study that included 19 eyes of 14 premature babies with posterior ROP and vitreous hemorrhage where conventional laser treatment could not be applied. Patients received an intravitreal injection of bevacizumab (Avastin) together with peripheral retinal cryotherapy.

**Results:** Vascularization began to regress within a few days after the injection, but vitreous hemorrhage absorbed more slowly. Repeat intravitreal injections of bevacizumab were administered in eight eyes within 1 month from the first injection. There were varying development of tractional retinal detachments in two of the eyes, but the ROP component quieted in all cases.

**Conclusion:** Off-label use of intravitreal bevacizumab with peripheral retinal cryotherapy appears to be useful as a treatment for posterior ROP when laser treatment is precluded. It improves dilatation, regressing and quiescent the disease and improves visibility.

### Biography

Mohamed Mostafa Kamel Diab has completed his PhD from Ain Shams University and Postdoctoral studies from Ain Shams University School of Medicine, Cairo, Egypt. He is a Professor of Ophthalmology, Ain Shams University, Cairo, Egypt and Consultant Ophthalmology Magrabi Hospital, KSA. He has published 16 international papers in reputed ophthalmology journals.

[mo\\_mustafaus@hotmail.com](mailto:mo_mustafaus@hotmail.com)

Notes: